Technical Analysis for SGTX - Sigilon Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 18.7938 | 7.82% | 1.36 |
SGTX closed down 1.86 percent on Monday, April 12, 2021, on 33 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | N/A | Down | Down |
Historical SGTX trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 7.82% | |
New 52 Week Low | Weakness | 7.82% | |
Wide Bands | Range Expansion | 7.82% | |
Down 3 Days in a Row | Weakness | 7.82% | |
Down 4 Days in a Row | Weakness | 7.82% | |
Down 5 Days in a Row | Weakness | 7.82% | |
Oversold Stochastic | Weakness | 7.82% | |
New 52 Week Closing Low | Bearish | 5.82% | |
New 52 Week Low | Weakness | 5.82% | |
Wide Bands | Range Expansion | 5.82% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Up 5% | about 1 hour ago |
60 Minute Opening Range Breakout | about 4 hours ago |
Rose Above Previous Day's High | about 4 hours ago |
Up 3% | about 4 hours ago |
Up 2% | about 4 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Disease Diabetes Health Sciences Hemophilia Chronic Disease Chronic Diseases Hemophilia A Mucopolysaccharidosis Haemophilia Mucopolysaccharidosis Type
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Disease Diabetes Health Sciences Hemophilia Chronic Disease Chronic Diseases Hemophilia A Mucopolysaccharidosis Haemophilia Mucopolysaccharidosis Type
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 54.32 |
52 Week Low | 16.55 |
Average Volume | 141,634 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 27.48 |
20-Day Moving Average | 20.89 |
10-Day Moving Average | 19.30 |
Average True Range | 2.59 |
ADX | 31.42 |
+DI | 11.31 |
-DI | 25.91 |
Chandelier Exit (Long, 3 ATRs ) | 22.58 |
Chandelier Exit (Short, 3 ATRs ) | 24.32 |
Upper Bollinger Band | 25.94 |
Lower Bollinger Band | 15.83 |
Percent B (%b) | 0.16 |
BandWidth | 48.42 |
MACD Line | -2.66 |
MACD Signal Line | -2.67 |
MACD Histogram | 0.008 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 19.57 | ||||
Resistance 3 (R3) | 19.51 | 18.74 | 19.21 | ||
Resistance 2 (R2) | 18.74 | 18.20 | 18.77 | 19.09 | |
Resistance 1 (R1) | 18.09 | 17.86 | 17.70 | 18.14 | 18.97 |
Pivot Point | 17.32 | 17.32 | 17.13 | 17.35 | 17.32 |
Support 1 (S1) | 16.66 | 16.77 | 16.28 | 16.72 | 15.89 |
Support 2 (S2) | 15.89 | 16.44 | 15.92 | 15.77 | |
Support 3 (S3) | 15.24 | 15.89 | 15.65 | ||
Support 4 (S4) | 15.29 |